Concepedia

S. Ou

SO

Statistics

Publications

6

Citations

184

H-Index

6

Active since

2007

Affiliations

Pfizer (United States)(Current)

S. Ou is an author at Pfizer (United States) specializing in oncology, medicine, and lung cancer.

Top concepts

Publications per year

2007–2012

6

Publications

6

A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

Chen Yang, Jen-Fu Shih, Wenmei Su et al. · Journal of Clinical Oncology · 2010 · 49 citations

, , +17

Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.

Weiwei Tan, Keith D. Wilner, Y. Bang et al. · Journal of Clinical Oncology · 2010 · 46 citations

, , +17

Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial

Joan H. Schiller, Timothy Larson, S. Ou et al. · Journal of Clinical Oncology · 2007 · 41 citations

, , +17

G6 Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066

E. L. Kwak, D. Ross Camidge, JeVrey W. Clark et al. · European Journal of Cancer Supplements · 2009 · 22 citations

, , +9

Clinical Activity of Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Ros1 Gene Rearrangement

S. Ou, D. Ross Camidge, J. A. Engelman et al. · Annals of Oncology · 2012 · 16 citations · Full text

, , +7

1–5 of 6